Faecalibacterium prausnitzii as Next Generation Probiotics

As the most abundant bacterial species found in the gut, Faecalibacterium prausnitzii (F. prausnitzii) has attracted increasing interest because of its potentially important role in promoting gut health. Recently, several reports highlighted the promising therapeutic strategy by counterbalancing dysbiosis using F. prausnitzii as a potentially active component of probiotic formulations. Based on our expertise in microbiota and microbiome science, Creative Biolabs is focused on providing process development & optimization and cGMP manufacturing services for next-generation probiotics (NGPs). F. prausnitzii is one important candidate of our NGPs portfolio.

Introduction of Faecalibacterium prausnitzii

Faecalibacterium prausnitzii.

Faecalibacterium prausnitzii (F. prausnitzii) is one of the main components of gut microbiota, constituting up to 15% of the total bacteria in the human gut. It belongs to the Faecalibacterium genus, Ruminococcaceae family (phylum Firmicutes). Generally, F. prausnitzii isolates share some characteristic as follows:

  • gram-stain negative, non-sporeforming, mesophilic, rod-shaped, acetate-consuming, and butyrate-producing, extremely oxygen-sensitive (EOS) or anaerobic member;
  • lack of epithelial cells adhesion, plasmids, anti-microbial, and hemolytic activity;
  • presence of DNAse activity.

Faecalibacterium prausnitzii and Diseases

F. prausnitzii depletion has been reported in several intestinal and metabolic disorders, celiac disease, and some cancers.

  • F. prausnitzii and Gastrointestinal Disorders
  • F. prausnitzii displays a crucial role in providing energy to the colonocytes as well as anti-inflammatory metabolites to maintain intestinal health. Accumulated evidence has demonstrated the link of decreased levels of F. prausnitzii with the onset and progression of inflammatory bowel diseases (IBD), a group of disorders characterized by chronic and relapsing inflammation of the gastrointestinal tract, such as Crohn's disease (CD) and ulcerative colitis (UC). Daily supplementation with F. prausnitzii can play an anti-inflammatory role in IBD.

    F. prausnitzii populations in healthy gut and in patients with IBD. Fig.2 F. prausnitzii populations in a healthy gut and patients with IBD. (Lopez-Siles, 2017)

  • F. prausnitzii and Celiac Disease
  • Celiac disease is an immune-based, chronic intestinal inflammatory diseases associated with the imbalance of the intestinal microbiome. It has been reported that the levels of F. prausnitzii are decreased in patients with celiac disease. Probiotic formulations with F. prausnitzii are appearing as an interesting adjuvant in the dietetic management of the celiac disease.

  • F. prausnitzii and Metabolic Disease
  • Obesity and diabetes are metabolic diseases characterized by inadequate calorie intake and/or abnormal energy metabolism. Some reports have demonstrated that in diabetics F. prausnitzii is presented in a very lower amount, indicating it is highly discriminant for diabetes.

    Novel strategies for diabetes prevention by dietary intervention of F. prausnitzii. Fig.3 Novel strategies for diabetes prevention by dietary intervention of F. prausnitzii. (Ganesan, 2018)

  • F. prausnitzii and Cancer
  • The relationship between F. prausnitzii and colorectal cancer (CRC) has become evident for a long time. In CRC patients, the level of F. prausnitzii is significantly decreased, showing fourfold reduction compared to healthy individuals. Therefore, this species may be a biomarker of choice to assist in CRC diagnosis and treatment.

Faecalibacterium prausnitzii Discovery at Creative Biolabs

F. prausnitzii is an extremely oxygen-sensitive bacterium, so its culture is very difficult, which greatly limits its basic research and clinical application. To reduce the gap between metagenomic and microbiological data, Creative Biolabs has devoted intense effort to isolate and characterize this species. Moreover, we are dedicated to developing commensal F. prausnitzii as potential NGP agents under strict criteria. Except for F. prausnitzii, we have developed a wide range of potential NGPs that can be applied for targeted therapy on specific inflammation or other diseases. What's more, we provide analyses & qualification and scale-up cGMP manufacturing services to meet different demands. We will work with you at all stages of the NGP development.

F. prausnitzii has been considered as a bioindicator and an actor of human health. If you want to know more information about this candidate discovery, please directly send us an e-mail or contact us for your special requests.

References

  1. Lopez-Siles, M.; et al. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. The ISME journal. 2017, 11(4): 841-852.
  2. Ganesan, K.; et al. Causal relationship between diet-induced gut microbiota changes and diabetes: a novel strategy to transplant Faecalibacterium prausnitzii in preventing diabetes. International journal of molecular sciences. 2018, 19(12): 3720.
CAT Product Name Product Overview
LBST-036FG Faecalibacterium prausnitzii; 27766 Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
LBST-037FG Faecalibacterium prausnitzii; 17677 Faecalibacterium prausnitzii was isolated from human feces. It is Gram-positive, mesophilic, rod-shaped, anaerobic.
LBST-038FG Faecalibacterium prausnitzii; 107838 Faecalibacterium prausnitzii was isolated from human feces. It is Gram-positive, mesophilic, rod-shaped, anaerobic.
LBST-039FG Faecalibacterium prausnitzii; 27768 Faecalibacterium prausnitzii was isolated from human feces. It is Gram-positive, mesophilic, rod-shaped, anaerobic.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutics Drug Discovery

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Contact us

Copyright © 2022 Creative Biolabs. All Rights Reserved.

Inquiry Basket